Rewriting the Code: The Future of CRISPR and Genetic Medicines

In this episode of “The Nucleus” by Regeneron, host Leah Sabin, PhD, Executive Director, Genetic Medicines at Regeneron, is joined by Janice Chen, PhD, co-founder and Chief Technology Officer at Mammoth Biosciences, for an in-depth conversation on the evolution and future of CRISPR technologies, and its impact on genetic medicines. The discussion explores how CRISPR has evolved: from cutting faulty genes to becoming a versatile platform for precision editing. It also touches on Mammoth’s development of ultra-compact nucleases and the ways in which Regeneron and Mammoth are collaborating to solve the challenge of delivery.

Recorded at the 2025 American Society of Gene & Cell Therapy (ASGCT) annual meeting, the episode dives into emerging trends like epigenetic editing, innovative delivery platforms, and strategies to mitigate immunogenicity. Leah and Janice examine industry challenges like off-target effects and the need for redosing, while emphasizing the importance of expanding gene editing beyond the liver to address a wider range of diseases. Together, they offer a forward-looking perspective on the future of CRISPR and the collaborative breakthroughs shaping tomorrow’s therapies.